| Meeting/Conference |
Date |
Lead Author |
Publication |
Clin Drug Investig |
October 2009 |
Niraj Vasisht, Ph.D. |
Formulation Selection and Pharmacokinetic Comparison of Fentanyl Buccal Soluble Film with Oral Transmucosal Fentanyl Citrate – A Randomized, Open-Label Single-Dose, Cross Over Study. Clin Drug Investig 2009: 29 (10) 647-654 |
American Academy of Pain Medicine |
January 2009 |
Niraj Vasisht, Ph.D. |
Dose Linearity, Consistency, and Predictability of BEMA® Fentanyl |
American Society of Regional Anesthesia and Pain Medicine |
November 2008 |
Niraj Vasisht, Ph.D. |
Adherence of and Fentanyl Absorption from the BEMA® Drug Delivery System |
American Society of Anesthesiologists |
October 2008 |
Niraj Vasisht, Ph.D. |
BEMA® Fentanyl Shows a Favorable Pharmacokinetic Profile and Dose Linearity in Healthy Volunteers
* Seach under term BEMA® * |
American Society of Anesthesiologists |
October 2008 |
James North, M.D. |
BEMA® Fentanyl Offers High Absolute Bioavailability and Favorable Efficacy and Tolerability Profiles
* Seach under term BEMA® * |
American Society of Clinical Oncology |
May 2008 |
Andrew Finn, PharmD |
Adverse Events Affecting the Mouth in Two Clinical Trials of BEMA® (BioErodible MucoAdhesive) Fentanyl |
American Society of Clinical Oncology |
May 2008 |
Olga Dib, DDS |
Absorption and Tolerability of BEMA® (BioErodible MucoAdhesive) Fentanyl in Cancer Subjects with Grade 1 Mucositis |
American Society of Clinical Oncology |
May 2008 |
David Blum, MD |
The Safety of BEMA® (BioErodible MucoAdhesive) Fentanyl for Breakthrough Pain in Cancer Patients |
American Society of Clinical Oncology |
May 2008 |
Rohit Kapoor, MD |
Rapid, Effective and Sustained Control of Breakthrough Pain in Cancer Patients Treated with BEMA® (BioErodible MucoAdhesive) Fentanyl |
Oncology Nurses Society |
May 2008 |
W.D. Charlie Hill, RN |
Rapid and Effective Control of Breakthrough Pain and Favorable Tolerability in Cancer Patients Treated with BEMA® (BioErodible MucoAdhesive Fentanyl) |
American Pain Society |
May 2008 |
David Blum, MD |
Adverse Events Affecting the Mouth: A Combined Analysis of Three Clinical Trials of BEMA® (BioErodible MucoAdhesive) Fentanyl |
American Pain Society |
May 2008 |
Niraj Vasisht, PhD |
Dose Linearity and Absolute Bioavailability of BEMA® (BioErodible MucoAdhesive) Fentanyl in Healthy Volunteers |
American Pain Society |
May 2008 |
Neal Slatkin, MD |
The Safety of BEMA® (BioErodible MucoAdhesive) Fentanyl Use for Breakthrough Pain in Cancer Patients |
American Pain Society |
May 2008 |
James North, MD |
Rapid and Effective Control of Breakthrough Pain and Tolerability in Cancer Patients Treated with BEMA® (BioErodible MucoAdhesive) Fentanyl |
